[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St. Olavs Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":649},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,50,81,116,145,167,199,226,253,274,299,322,350,376,396,417,436,463,483,502,533,560,589,608,628],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100250641","acute-and-long-term-cardiovascular-toxicity-after-modern-radiotherapy-for-breast-cancer-100250641",false,"NCT02541435","Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer","Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer - a Prospective Longitudinal Study","Inclusion Criteria:\n\n* diagnosis of breast cancer\n* expected life-expectancy above 10 years\n\nExclusion Criteria:\n\n* Not willing to participate","FEMALE","30 Years","70 Years",{"count":21,"type":22},1600,"ESTIMATED","OBSERVATIONAL","In Europe, breast cancer is by far the most common form of cancer diagnosed in women today, accounting for 29% of all cases. The 5-year survival rate is approximately 90%. Surgery is usually combined with radiotherapy (RT), anthracyclines, aromatase inhibitors and\u002For trastuzumab (Herceptin) which all have improved the life expectancy and survival in breast cancer patients.\n\nUnfortunately, RT is associated with a broad spectrum of cardiovascular diseases, which includes coronary artery disease, valvular dysfunction, congestive heart failure and stroke, and is the most common non-malignancy cause of death. During the last two decades, RT regimens for breast cancer have changed and the doses of radiation to which the heart is exposed are now potentially lower due to new and improved RT techniques. However, there are no data on whether these new regimes decrease the risk of cardiovascular disease.\n\nIn this study the incidence and prevalence of cardiovascular diseases will be estimated 8 and 15 years after both conventional and laser assisted breath controlled RT, and compared with cardiovascular diseases in the general female population. A further aim is to evaluate signs and prevalence of acute cardiotoxicity from RT with the use of cardiac magnetic resonance imaging, coronary fractional flow reserve, ECG and inflammatory and cardiac biomarkers and to investigate whether these signs can predict later cardiovascular disease. The importance of traditional cardiovascular risk factors (age, hypertension, hypercholesterolemia, smoking habits and physical activity, as registered before RT) will also be evaluated.",[26,27],"Breast Neoplasms","Cardiovascular Diseases",[29,30,31,32,33,34,35,36],"Radiotherapy","Biological markers","Magnetic resonance imaging","Echocardiography","Tomography, X-Ray Computed","Risk factors","Heart","Quality of Life","RECRUITING","2026-06-02",{"date":40,"type":41},"2026-06-04","ACTUAL",{"date":43,"type":41},"2016-11",{"date":45,"type":22},"2036-12",{"name":47,"class":48},"St. Olavs Hospital","OTHER",2,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100353874","group-based-stabilization-and-skill-training-for-patients-with-lasting-posttraumatic-reactions-in-mental-health-care-100353874","NCT03887559","Group-based Stabilization and Skill Training for Patients With Lasting Posttraumatic Reactions in Mental Health Care","Adding a Group Based Stabilization and Skill Training Intervention for Patients With Long Lasting Posttraumatic Reactions Receiving Outpatient Treatment in Specialized Mental Health Care - A Randomized Controlled Trial","Inclusion Criteria:\n\n* Receiving treatment in ordinary out-patient clinics\n* Having been exposed to or witnessing to traumatic event(s) defined as \"one or several extremely threatening or horrific events or series of events or situations being of such a character which is likely to overwhelming distress in almost anyone in a similar situation\", measured by Stressful Life Events Screening Questionnaire\n* Presenting with posttraumatic reactions such as hyperarousal, avoidance, intrusions, emotional dysregulation or interpersonal difficulties.\n* Symptom duration for a minimum of six months.\n* Understand and speak Norwegian to an extent that is required to participate in a stabilization- and skill-training group.\n\nExclusion Criteria:\n\n* Active psychotic symptoms.\n* Substance or drug addiction or abuse.\n* High suicidal risk considered by the individual therapist.\n* Having participated in the course previously.","ALL","18 Years","75 Years",{"count":61,"type":22},160,"INTERVENTIONAL",[64],"NA","This study evaluates the addition of a group based stabilization and skill-training intervention to individual out-patient treatment for long lasting post-traumatic reactions. Half of the participants will receive the combined treatment while the other half will receive individual treatment as usual.",[67,68,69],"Stress Disorders, Post-Traumatic","Mental Disorders","Trauma and Stressor Related Disorders",[71],"Psychotherapy","2026-04-24",{"date":74,"type":41},"2026-04-30",{"date":76,"type":41},"2019-03-25",{"date":78,"type":22},"2027-12",{"name":47,"class":48},1,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":57,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":94,"conditions":95,"keywords":103,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":80},"100565751","neodoppler-new-ultrasound-technology-for-continuous-monitoring-of-cerebral-circulation-pilot-100565751","NCT06646250","NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot","NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Blood Flow in Infants","CE-NeoDoppler","Inclusion Criteria:\n\n* Open fontanelle\n* Healthy preterm or term born neonates\n* Neonates with a medical condition of interest according to the different cohort studies: patent ductus arteriosus, perinatal asphyxia, stroke, pulmonary hypertension, congenital heart condition or infection\u002Fsepsis\u002Fmeningitis\n* Neonates in need of procedures\n\nExclusion Criteria:\n\n* Caregivers not understanding\u002Fspeaking Norwegian or English\n* Caregivers not giving their consent",true,"0 Minutes","12 Months",{"count":93,"type":22},180,"Non-invasive tools for monitoring of course of disease are important and necessary in the treatment of pre-term\u002Fpremature infants and sick neonates. For many years, the ultrasound group in Trondheim has been at the forefront in the development of new ultrasound technology for the diagnosis and monitoring of disease. Several methods previously developed in this research group are today widely used in hospitals around the world. In this project the investigators aim to test a new ultrasound technology that allows continuous monitoring of cerebral blood flow in sick neonates and pre-term children. This technology was CE-certified in October 2022, and in this project the investigators will test the CE-certified version with the newest available approved software.",[96,97,98,99,100,101,102],"Preterm","Patent Ductus Arteriosus","Sepsis","Asphyxia","Stroke","Pulmonary Hypertension","Congenital Heart Disease",[104,105,106,107],"Cerebral Doppler","Monitoring","Continuous","Neonate","2026-04-22",{"date":110,"type":41},"2026-04-23",{"date":112,"type":41},"2024-10-20",{"date":114,"type":22},"2029-12-31",{"name":47,"class":48},{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":89,"sex":57,"minAge":58,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":62,"phases":127,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},"100535195","phase-2-prophylactic-treatment-with-atorvastatin-for-episodic-migraine-100535195","NCT06248671","Prophylactic Treatment With Atorvastatin for Episodic Migraine.","EpisodicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Episodic Migraine","EStatinMig","Inclusion Criteria:\n\n* Age 18 to 65 years.\n* Signed informed consent.\n* Episodic migraine with or without aura according to ICHD-3 criteria.\n* At inclusion, patients should retrospectively have from 4 to 14 migraine attacks per month during the last 3 months. This frequency must be confirmed in the headache diary before randomisation to treatment.\n* Debut of migraine at least one year prior to inclusion based on information in the patient record or by careful examination of previous headache history.\n* Start of migraine before 50 years.\n* No use of other migraine prophylactics during the study.\n* For women of child-bearing potential, there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception.\n\nAfter the baseline period, just before randomisation to the study drug, inclusion criteria will be evaluated once more, and the headache diary will be evaluated. If there are, according to the headache diary, fewer attacks than 4 or more than 14 per month, the baseline period can be extended to 8 weeks, and the patient can be randomized to a treatment then if there is a mean of 4-14 attacks per 4 weeks during the 8-week's period.\n\nExclusion Criteria:\n\n* Interval headache not distinguishable from migraine.\n* Chronic migraine, chronic tension-type headache, medication overuse headache or other headache occurring on ≥ 15 days\u002Fmonth.\n* Pregnancy, planning to get pregnant, inability to use contraceptives, and lactating.\n* Clinical information on or signs of cholestasis or decreased hepatic or renal function.\n* High degree of comorbidity and\u002For frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator.\n* Hypersensitivity to statins or previous use of statins.\n* History of angioneurotic oedema.\n* Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study.\n* Current use of antiviral treatment against hepatitis C.\n* Significant psychiatric illness.\n* Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years.\n* Requiring detoxification from acute medication (triptans, opioids).\n* Consistently failing to respond to any acute migraine medication.\n* Alcohol or illicit drug dependence.\n* Inability to understand study procedures and to comply with them for the entire length of the study.\n* Treatment for hypothyroidism.\n* Lactose intolerance.","65 Years",{"count":126,"type":22},450,[128],"PHASE2","The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.",[131],"Episodic Migraine",[133,134,135],"Migraine","Atorvastatin","Randomized controlled trial","2026-02-16",{"date":138,"type":41},"2026-02-19",{"date":140,"type":41},"2024-05-01",{"date":142,"type":22},"2029-02-28",{"name":47,"class":48},6,{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":62,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":80},"100492400","chronotherapy-for-depressive-episodes-100492400","NCT05691647","Chronotherapy for Depressive Episodes","Chronotherapy for Patients With a Depressive Episode in a Public Mental Health Care Clinic in Norway: A Randomized Controlled Trial","Inclusion criteria. Patients eligible for the trial must comply with all the following at randomization:\n\n* Being 18 years or older\n* Willing and able to provide a written informed consent\n* Newly diagnosed with an ongoing moderate or severe depressive episode according to the International Classification of Disorders 10th edition (ICD-10) and accepted for treatment for the depressive episode. The diagnosis is set in consensus of a licensed therapist and a specialist in psychiatry\u002Fpsychology.\n* The patient must score ≥ 9 on the Hamilton Depression Rating Scale-6.\n* Must be able to communicate in a Scandinavian language\n\nExclusion criteria. Patients are considered ineligible for participation if any of the following are present:\n\n* Illnesses and treatments where chronotherapy may be contraindicated (for example epilepsy, ongoing attack of multiple sclerosis, blindness, narcolepsy and psychotic depression, ECT treatment).\n* Known pregnancy.\n* Individuals with a known diagnosis of emotionally unstable personality disorder (F60.3).\n* Individuals with a known psychotic disorder\n* Shiftwork or other related social or work circumstances that inhibit participation\n* Participation in an ongoing trial at the outpatient clinic that encompasses digital cognitive behavior therapy for insomnia (recruitment to this trial will end in 2023).","100 Years",{"count":154,"type":22},76,[64],"Evidence-based treatments for depression, such as antidepressive medication, usually have a latency of 4 to 6 weeks before they achieve a therapeutic effect. Chronotherapy is a group of non-pharmacological interventions that presumably act on the circadian system to achieve a rapid-onset clinical effect and better long-term effects and has been shown efficient to improve depressive symptoms. Interventions include sleep deprivation, sleep-phase advancement and stabilization, and light therapy. There are few studies testing the effectiveness of combining these three chronotherapeutic techniques in the initial phase of treatment of depression in a mental health care clinic. The investigators aim to test the effects and safety of chronotherapy in addition to TAU compared to TAU alone, with the primary outcome being self-reported depressive symptoms at 1 week following randomization. The study is a randomized controlled trial with 76 patients with a depressive episode who initiate treatment at Nidaros DPS, St. Olavs University Hospital. Participants will be allocated 1:1 to either chronotherapy + treatment as usual (TAU) or to TAU alone.",[158],"Depressive Episode","2025-12-30",{"date":161,"type":41},"2025-12-31",{"date":163,"type":41},"2023-04-12",{"date":165,"type":22},"2040-01",{"name":47,"class":48},{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":62,"phases":178,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100616393","pelvic-pain-electro-acupuncture-100616393","NCT07305025","Pelvic Pain Electro-Acupuncture","Pelvic Pain Electro-Acupuncture: Randomized Study for Symptom Liberation","PEARL","Inclusion Criteria:\n\n* Women aged 18-45 years referred for diagnostic laparoscopy with suspicion of endometriosis\n* Experiencing moderate to severe pelvic pain\n* Willing to commit to the treatment schedule and follow-up\n* Understanding Norwegian or English to be able to communicate and fill out questionnaires\n\nExclusion Criteria:\n\n* Pregnancy\n* Use of opioid pain relief\n* Concurrent participation in other pain management trials","45 Years",{"count":177,"type":22},38,[64],"The aim of the study is to investigate if a series of up to 9 treatment sessions of electroacupuncture can be used to alleviate pain in women with suspected endometriosis, scheduled for diagnostic laparoscopy",[181,182],"Pelvic Pain","Endometriosis",[184,185,186,187,188,189],"pelvic pain","endometriosis","acupuncture","sexual function","quality of life","pelvic floor muscle function","NOT_YET_RECRUITING","2025-12-11",{"date":193,"type":41},"2025-12-26",{"date":195,"type":22},"2025-12-15",{"date":197,"type":22},"2027-04-30",{"name":47,"class":48},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":62,"phases":209,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":80},"100611798","phase-2-adjuvant-tranexamic-acid-txa-versus-surgery-alone-for-adult-patients-with-chronic-subdural-hematoma-csdh-100611798","NCT07245264","Adjuvant Tranexamic Acid (TXA) Versus Surgery Alone for Adult Patients With Chronic Subdural Hematoma (CSDH)","Randomized Trial Comparing Adjuvant Tranexamic Acid Versus Surgery Alone For Chronic Subdural Hematoma","RATATA","Inclusion Criteria:\n\n1. Symptomatic chronic subdural hematoma confirmed on computer tomography (CT) or magnetic resonance imaging (MRI) measuring greater than 10 mm thickness.\n2. Adult patient ≥18 years\n3. Scheduled for single or double burr hole for evacuation.\n4. No contraindication for TXA\n\nExclusion criteria\n\n1. Mechanical heart valve\n2. Newly diagnosed (last 12 months) pulmonary embolism, myocardial infarction, and strong indication for antithrombotic treatment\n3. Intracranial surgery within last 6 months\n4. Pregnancy and woman\\\u003C40 years\n5. Participation in any other clinical trial\n6. Life expectancy of less than one year.\n7. A score on the modified Rankin scale, designed to assess functional independence, of 4 or 5 (scores range from 0 \\[no symptoms\\] to 6 \\[death\\]) before the hematoma occurred.\n8. Unfit for participations for any other reason as evaluated by the including physician.\n9. History of severe impairment of renal function (eGFR \\\u003C30ml\u002Fmin or serum creatinine \\>150μmol\u002FL)\n10. Known hypersensitivity or allergy to TXA\n11. Inability to obtain informed consent from the patient or legal representative",{"count":208,"type":22},274,[128,210],"PHASE3","This study is an open label randomized controlled trial. Patients with a symptomatic Chronic Subdural Hematoma (CSDH) confirmed on radiological imaging, planned for surgery, age over 18, free from other intracranial pathologies and no previous intracranial surgery, will be recruited at time of admission. Patients eligible for inclusion will be randomized to receive treatment with Tranexamic acid (TXA) as an adjunct to surgery or surgery alone. Surgical evacuation will be performed using a single or double burr hole and 24 hours postoperative drainage. The primary endpoint will be recurrent hematoma requiring repeat surgery within 90 days. Secondary outcomes will be modified Rankin Scale at 90 days, EQ-5D-5L, complications and adverse events, and 90-day mortality.",[213],"Chronic Subdural Hematoma",[215,216,217],"Chronic subdural hematoma","Tranexamic acid","Neurosurgery","2025-12-01",{"date":220,"type":41},"2025-12-08",{"date":222,"type":22},"2025-12-10",{"date":224,"type":22},"2029-06-01",{"name":47,"class":48},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":124,"enrollmentInfo":232,"targetDuration":4,"studyType":62,"phases":234,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":80},"100562502","goal-management-training-gmt-for-improvement-of-cognitive-control-function-after-acquired-brain-injury-100562502","NCT06604000","Goal Management Training (GMT) for Improvement of Cognitive Control Function After Acquired Brain Injury","Inclusion Criteria:\n\n* Patients aged 18-65 with acquired brain injury with no concomitant diseases minimum 12 months' post-injury\u002Fsurgery, reporting cognitive control problems by structured interview or clinical performance measures.\n\nExclusion Criteria:\n\n* Non-fluency in Norwegian Language\n* Major psychiatric disorder or reported ongoing alcohol or substance abuse.\n* Premorbid neurological disease or insult and\u002For comorbid neurological disease.\n* Aphasia or other specified language problems causing potential communication problems.\n* Impaired basic linguistic, mnemonic, motor, or perceptual function that can interfere with the ability to engage with training or estimated IQ \\\u003C 85",{"count":233,"type":22},116,[64],"The goal of this clinical trial is to investigate predictors of treatment outcome, and the effect of individual treatment components of Goal Management Training (GMT) for improvement of cognitive control function in people with acquired brain injury (ABI).\n\nPrimary aim: To identify demographic, clinical and cognitive predictors of treatment response in Goal Management Training after acquired brain injury (ABI)?\n\nSecondary aims: To investigate the effects of a) extended cuing (via a smartphone) and b) a booster module?\n\n* All included participants will receive Goal Management Training in groups of 4-6 patients, as implemented in a rehabilitation hospital setting (St. Olavs Hospital, Trondheim University Hospital). The standard treatment (\"GMT Usual\") consists of 10 sessions, delivered as 2 sessions a day, one day per week, over 5 weeks.\n* All participants will be asked to complete self-report measures and performance-based cognitive testing at baseline (T1), immediately after the main treatment period (T2), at 6 months (T3), and 1 year (T4) after treatment.\n* After baseline assessment, 50% of participants will be randomized to receive extended cuing through a smartphone application (\"GMT Cuing\") - intended to facilitate the effect of between-session tasks (homework) completed by the participants. These participants will, in addition to the standard treatment, on a daily basis receive a message that says \"STOP\" as a reminder to do their home assignments.\n* After completion of the 10 GMT sessions and the first post-treatment assessment immediately after the main treatment period, 50% of the participants will be randomized to receive an additional booster module (\"GMT Boost\") 3 months after the last ordinary GMT module - intended to facilitate a prolonged treatment response. The remaining 50% will receive no booster module (\"GMT No Boost\")\n* Randomization will be carried out on treatment group-level (all patients in the same group receive the same treatment). The total anticipated sample size is N = 116 patients.\n* The Global Executive Composite (GEC) score derived from BRIEF-A will be used as the primary outcome measure. A selection of other included measures will be used as secondary outcome measures.",[237,238],"Acquired Brain Injury","Executive Function Disorder",[240,241,242,243,244,245],"acquired brain injury","goal management training","executive function","cognitive control","GMT","cognitive rehabilitation",{"date":247,"type":41},"2025-12-02",{"date":249,"type":41},"2023-09-26",{"date":251,"type":22},"2030-01-01",{"name":47,"class":48},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":62,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":4},"100606813","piloting-18f-fapi-petmri-for-applications-in-breast-cancer-100606813","NCT07180433","Piloting 18F-FAPI PET\u002FMRI for Applications in Breast Cancer","Inclusion Criteria:\n\n* Inclusion criteria are accepting to undergo 18F-FAPI PET\u002FMRI examinations and\n\n  1. diagnosed with local invasive breast cancer,\n  2. scheduled for neoadjuvant therapy as primary treatment,\n  3. has recurrent or new breast cancer, or\n  4. scheduled for neoadjuvant therapy as primary treatment with FDG-PET\u002FCT applied for staging.\n\nExclusion Criteria:\n\n* other primary malignancies than breast cancer, renal insufficiency or know allergy towards contrast agents, and MR incompatible implants.","80 Years",{"count":261,"type":22},60,[64],"Breast cancer is the most common type of cancer in Norwegian women, with 4,224 new cases in 2022. More precise diagnosis are expected to result in more accurate assessment of treatment effect, and to contribute to both providing better treatment and reducing overtreatment. Fibroblast activating protein (FAP) is expressed in the tumor stroma of 90% of all epithelial-based tumors, including breast tumors. Inhibitors for this protein (FAPI) has been developed for use as radioactive tracers. Breast tumors of various histopathological types, and local metastatic lymph nodes, have shown high uptake for such tracers. The main aim of this project is to establish 18F-FAPI PET\u002FMRI for use in breast cancer in a wide range of disease stages. We will evaluate how FAPI PET\u002FMRI correlates with histopathological assessment, the method's ability to grade tumors - including assessment of treatment - compared to CT, scintigraphy and FDG PET\u002FCT, and ability to detect local recurrence.",[265],"Breast Neoplasm Female","2025-09-11",{"date":268,"type":41},"2025-09-18",{"date":270,"type":22},"2025-10-01",{"date":272,"type":22},"2038-12-31",{"name":47,"class":48},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":62,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":49},"100279542","fixation-of-patellar-tendon-grafts-in-anterior-cruciate-ligament-reconstruction-endobutton-vs-metal-interference-screws-100279542","NCT02918734","Fixation of Patellar Tendon Grafts in Anterior Cruciate Ligament Reconstruction. Endobutton vs Metal Interference Screws","A Prospective Randomized Controlled Trial Comparing the Endobutton CL BTB Fixation System With Metal Interference Screws in the Femoral Fixation of Patellar Tendon Grafts in Anterior Cruciate Ligament Reconstruction.","Inclusion Criteria:\n\n* Primary reconstruction of ACL ruptures\n* Surgery at least 6 weeks after injury\n* The patient must accept and sign the informed consent form before surgery\n\nExclusion Criteria:\n\n* Medical indication for using another graft than BPTB autograft (such as history of anterior knee pain or occupations etc. requiring frequent kneeling)\n* Previous major surgical procedures in the same knee\n* Major additional injuries in the knee (posterior cruciate ligament, lateral collateral ligament, medial collateral ligament, sutured meniscus lesions and major cartilage lesions undergoing cartilage repair)\n* Contralateral ACL injury (treated or untreated)\n* Present or former serious illness that makes follow-up or rehabilitation difficult (e.g. alcohol or drug abuse, psychiatric disease)","55 Years",{"count":283,"type":22},220,[64],"In this randomized controlled trial the investigators will compare the results after primary anterior cruciate ligament (ACL) reconstruction using two different methods for femoral fixation of a bone-patellar tendon-bone (BPTB) autograft. Interference screws have been the standard method for fixing the femoral side of BPTB grafts; however, several pitfalls have been reported. Cortical fixation with the Endobutton CL BTB Fixation System has become available and the clinical results have been described as promising; however, no randomized controlled trials comparing these two femoral fixation methods have been conducted, and there is no published data that confirms that the bone block heals in the tunnel with the newer method.\n\nThe aim of our study is to compare the outcome after primary ACL reconstruction with BPTB autografts using the Endobutton CL BTB or metal interference screw for femoral fixation.",[287],"Knee Injuries",[289,290],"Anterior Cruciate Ligament","Bone-Patellar Tendon-Bone Grafting","2025-07-09",{"date":293,"type":41},"2025-07-10",{"date":295,"type":41},"2016-10",{"date":297,"type":22},"2033-03",{"name":47,"class":48},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":62,"phases":309,"briefSummary":310,"conditions":311,"keywords":314,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":321,"locationsCount":80},"100563555","effect-of-patient-education-on-drinking-behaviour-and-oral-hygiene-in-patients-undergoing-bariatric-surgery-100563555","NCT06617689","Effect of Patient Education on Drinking Behaviour and Oral Hygiene in Patients Undergoing Bariatric Surgery","Effekt av Pasientundervisning på Drikkevaner og Munnhygiene Hos Pasienter Som gjennomgår Fedmekirurgi","BAR-VANNTANN","Inclusion Criteria:\n\n* Eligible for bariatric surgery at a Norwegian hospital\n\nExclusion Criteria:\n\n* Insufficient language skills\n* Lack of consent competency",{"count":308,"type":22},300,[64],"The background for the study is that many bariatric surgery patients struggle with their oral health after bariatric surgery. This is probably related to both physiological changes and changes in eating and drinking patterns. In addition, many have reduced oral health even before surgery, and a significant proportion also have dental treatment anxiety, which also affects their ability to seek dental treatment. In sum, this is probably a patient group that may be at risk of oral pathology.\n\nParticipants in the study will be randomly allocated to different patient education programmes. The three interventions are:\n\n1. customised information on a website\n2. education delivered by a clinician\n3. distribution of free samples relevant to dental hygiene\n\nThe outcomes recorded are level of knowledge, drinking patterns, self-perceived oral health, and oral hygiene routines.",[312,313],"Obesity","Bariatric Surgery Candidate",[312,315],"Oral health","2025-07-07",{"date":293,"type":41},{"date":319,"type":41},"2025-01-28",{"date":114,"type":22},{"name":47,"class":48},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":124,"enrollmentInfo":329,"targetDuration":4,"studyType":62,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":80},"100537963","the-effect-of-a-brief-educational-intervention-for-adults-with-adhd-100537963","NCT06284655","The Effect of a Brief Educational Intervention for Adults With ADHD","The Effect of a Brief Educational Intervention for Adults With ADHD: a Randomized Control Trial","Inclusion Criteria:\n\n* Confirmed ADHD-diagnosis\n* Speaking a Scandinavian language\n* Willing to participate\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* In-patient on a acute psychiatric ward\n* Severe learning difficulties\n* Involvement in other research studies",{"count":261,"type":22},[64],"This RCT-study proposes the evaluation of an intensive educational intervention tailored for adults with Attention Deficit Hyperactivity Disorder (ADHD) in community mental health centers (CMHCs). Given the prevalent challenges of prolonged waiting lists and low patient engagement in CMHCs, the research seeks to assess the efficacy of this intervention in enhancing patient engagement, self-efficacy, satisfaction with the information and overall health outcomes. The intervention, developed collaboratively with user representatives, combines a brief group-based educational sessions with standard clinical care. The primary hypotheses posit that this approach will lead to increased patient satisfaction with the treatment, patient self-efficacy, and activation compared to conventional treatment. Additionally, it aims to improve patients' satisfaction with information received. The study will employ a ITT analysis to assess the intervention's effects against usual treatment practices in outpatient settings. The anticipated outcome is a significant improvement in level of patient satisfaction, level of self-efficacy and level of satisfaction with the received information for patients with ADHD, potentially informing clinical practices and optimizing care for adults with ADHD.",[333],"ADHD",[333,335,336,337,338,339,340,341,342],"patient education","psychoeducation","patients' satisfaction","general self-efficacy","self-management","self-management skills","group-based education","peer co-led",{"date":344,"type":41},"2025-07-08",{"date":346,"type":41},"2025-02-14",{"date":348,"type":22},"2030-12",{"name":47,"class":48},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":124,"enrollmentInfo":357,"targetDuration":4,"studyType":62,"phases":359,"briefSummary":360,"conditions":361,"keywords":366,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":80},"100517277","exercise-in-postconcussion-symptoms-and-posttraumatic-headache-100517277","NCT06015451","Exercise in Postconcussion Symptoms and Posttraumatic Headache","Exercise Interventions in Patients With Postconcussion Symptoms and Posttraumatic Headache. A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age 18-65 years\n* Having sustained a minimal head injury or mild traumatic brain injury at least 2 weeks ago.\n* At least one postconcussion symptoms, of at least moderate degree, occurring within the first week after the head injury.\n* Intolerance for physical activity (self-reported and measured; including symptom exacerbation later on the test day).\n* Capable of giving informed consent.\n\nExclusion Criteria:\n\n* More than 2 years since last injury.\n* The symptoms are better explained by other conditions.\n* Severe communication problems, typically due to poor knowledge of Norwegian.\n* Severe psychiatric, neurological, somatic, or substance abuse disorders that will make it problematic to function in a group and\u002For will complicate follow-up and outcome assessment.\n* Safety concerns according to the study medical checklist.",{"count":358,"type":22},100,[64],"The goal of this clinical trial is to compare two models of delivery of guided exercise in patients with exercise intolerance after mild head injury.\n\nThe main question it aims to answer is:\n\n• Is a program that includes elements of in-house exercise and follow-up sessions, and repeated treadmill testing, superior to a program with telephone-based follow-up only?\n\nParticipants will undergo a treadmill test to determine eligibility for the study, and to determine at what intensity level their symptoms worsen (symptom threshold). Thereafter they will exercise 15-20 minutes, 3-5 times per week at 80-90% of the heart rate that was found to be the symptom threshold. One group will receive face-to-face folllow-up and repeated testing, one group will receive telephone-based follow-up only .\n\nResearchers will compare these two groups to see if closer follow-up is superior when it comes to recovery from exercise intolerance after 12 weeks of exercise.",[362,363,364,365],"Brain Concussion","Post-Concussion Syndrome","Post-Traumatic Headache","Craniocerebral Trauma",[367,368,369],"exercise intolerance","exercise","Thread mill test",{"date":344,"type":41},{"date":372,"type":41},"2022-11-01",{"date":374,"type":22},"2026-09-01",{"name":47,"class":48},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":124,"enrollmentInfo":383,"targetDuration":4,"studyType":62,"phases":385,"briefSummary":386,"conditions":387,"keywords":388,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":80},"100409702","acceptance-and-commitment-therapy-based-rehabilitation-of-post-concussion-symptoms-100409702","NCT04614922","Acceptance and Commitment Therapy-based Rehabilitation of Post-concussion Symptoms","Acceptance and Commitment Therapy-based Rehabilitation of Post-concussion Symptoms: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Having sustained a minimal HI or MTBI\n* PCS\u002F PTH had evolved within 1 week after the head trauma.\n* At least one post-concussion symptoms of at least moderate degree, that affects daily life.\n* \\> 6 months post-injury.\n* First line treatment has been tried, e.g. psychoeducation, increase of physical activity and pharmacological treatments for headache\n\nExclusion Criteria:\n\n* More than 5 years since last injury.\n* Symptoms are better explained by other conditions.\n* Severe communication problems, typically due to poor knowledge of Norwegian.\n* Severe psychiatric, neurological, somatic or substance abuse disorders that will make it problematic to function in a group and\u002For will complicate follow-up and outcome assessment.",{"count":384,"type":22},48,[64],"The investigators aim to evaluate effects of an outpatient rehabilitation program based on Acceptance and Commitment Therapy compared to usual care on function in patients with post-concussion syndrome (PCS) and post-traumatic headache (PTH). This study builds on the investigators' previous observational studies and treatment studies in this patient group.",[363,364],[389],"Acceptance and Commitment Therapy",{"date":344,"type":41},{"date":392,"type":41},"2020-10-29",{"date":394,"type":22},"2026-11",{"name":47,"class":48},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":62,"phases":404,"briefSummary":405,"conditions":406,"keywords":408,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":416},"100365544","spinal-cord-stimulation-for-refractory-pain-in-erythromelalgia-100365544","NCT04039633","Spinal Cord Stimulation for Refractory Pain in Erythromelalgia","Inclusion Criteria:\n\n1. A diagnosis of primary or idiopathic erythromelalgia\n2. Patients ≥18 years who have developed chronic pain that has remained refractory to medical treatment for ≥6 months.\n3. Minimum pain intensity of 5\u002F10 on a numeric rating scale NRS at baseline.\n4. Successful two-week SCS testing period with tonic stimulation (≥2 points reduction in pain NRS from baseline). This means patients will experience paresthesia during the trial period of spinal cord stimulation.\n\nExclusion Criteria:\n\n1. Coexisting conditions that would increase procedural risk (e.g., sepsis, coagulopathy).\n2. History of laminectomy or posterior fusion at the thoracolumbar junction, where percutaneous electrode end tips are routinely placed.\n3. Abnormal pain behavior and\u002For unresolved psychiatric illness.\n4. Unresolved issues of secondary gain or inappropriate medication use.\n5. Unfit for participation for any other reason as judged by the study physician.",{"count":403,"type":22},24,[64],"Erythromelalgia is a rare disorder characterized by red, warm, and painful extremities, which is often precipitated by warm conditions. The pathophysiology is incompletely understood. The management of pain in erythromelalgia is challenging as no single therapy has been found to be effective. Response to pharmacotherapy varies, meaning that the physician has to take a stepwise trial and error approach with each patient. Consequently, this disorder is often associated with poorer health-related quality of life. There is currently no consensus or guideline on management of pain in erythromelalgia. Spinal cord stimulation is a widely applied therapy to treat severe chronic pain of various origin. Case reports and anecdotal evidence suggest that this therapy might alleviate refractory pain in patients with erythromelalgia.\n\nThe aim of this trial is to evaluate the efficacy of spinal cord stimulation for refractory pain in erythromelalgia.",[407],"Erythromelalgia",[409],"Spinal Cord Stimulation",{"date":344,"type":41},{"date":412,"type":41},"2019-08-26",{"date":414,"type":22},"2026-01",{"name":47,"class":48},4,{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":89,"sex":57,"minAge":58,"maxAge":124,"enrollmentInfo":424,"targetDuration":4,"studyType":62,"phases":425,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":434,"leadSponsor":435,"locationsCount":144},"100553380","phase-2-prophylactic-treatment-with-atorvastatin-for-chronic-migraine-chronicstatinmig-100553380","NCT06485336","Prophylactic Treatment With Atorvastatin for Chronic Migraine (ChronicStatinMig)","ChronicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Chronic Migraine","Inclusion Criteria:\n\n1. Age 18 to 64 years\n2. Signed informed consent\n3. Chronic migraine according to ICHD-3 criteria (32)\n4. At inclusion, patients should retrospectively have at least 15 headache days per month wheof at least 8 migraine days during the last 3 months. This frequency must be confirmed in the headache diary before randomisation to treatment (See below).\n5. Debut of migraine at least one year prior to inclusion based on information in the patient record or by careful examination of previous headache history\n6. Start of migraine before age 50 years.\n7. No use of other migraine prophylactics during the study\n8. For women of child-bearing potential (WOCBP, see below) there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception (See below).\n\nAfter the baseline period, just before randomisation to the study drug, inclusion criteria will be evaluated once more, and the headache diary will be evaluated. If there are, according to the headache diary, fewer migraine days than 8 per month, the baseline period can be extended to 8 weeks.\n\nExclusion Criteria:\n\n1. Medication overuse headache requiring detoxification from acute medication (triptans, opioids). Exception could be made for those fulfilling A and B:\n\n   A. Have tried a withdrawal period of at least 2 months without impact on headache frequency B: Use of opioids (of any type) ≤ 8 days \u002Fmonths.\n2. Pregnancy, planning to get pregnant, inability to use contraceptives (See inclusion criteria, point 8), and lactating\n3. Clinical information on or signs of cholestasis or decreased hepatic or renal function.\n4. High degree of comorbidity and\u002For frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator\n5. Hypersensitivity to statins or previous use of statins\n6. History of angioneurotic oedema\n7. Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study\n8. Current use of antiviral treatment agaist hepatitis C\n9. Significant psychiatric illness\n10. Alcohol or illicit drug dependence.\n11. Inability to understand study procedures and to comply with them for the entire length of the study\n12. Treatment for hypothyroidism\n13. Lactose intolerance",{"count":308,"type":22},[128],"The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 2) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.",[428],"Chronic Migraine",[133,134,135],"2025-06-29",{"date":432,"type":41},"2025-07-01",{"date":140,"type":41},{"date":142,"type":22},{"name":47,"class":48},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":89,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":62,"phases":446,"briefSummary":447,"conditions":448,"keywords":451,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":80},"100567539","the-sleep-clinic-outcome-and-practice-study-100567539","NCT06669507","The Sleep Clinic Outcome and Practice Study","The Sleep Clinic Outcome and Practice Study: The SUP-study","SUP","Inclusion Criteria:\n\n* Referred to the Sleep Clinic at St. Olavs Hospital for an assessment of a sleep-wake disruption.\n* Age \\>= 18 years.\n* Willing and able to provide written informed consent.\n* Meeting the diagnostic criteria for at least one of the following disorders: F51.0 Insomnia disorder or G47.2 Sleep-wake rhythm disorders, considered being either: Delayed sleep-wake phase disorder, Advanced sleep-wake phase disorder, Non-24-hour sleep-wake disorder or Irregular sleep-wake disorder\n* Desire non-pharmacological sleep treatment\n\nExclusion Criteria:\n\n* Individuals working night shifts or that otherwise have external conditions that result in inadequate sleep opportunity, such as caring for an infant or does not have permanent housing etc.\n* Individuals being blind\n* Individuals being psychotic\n* Individuals having epilepsy\n* Individuals having an ongoing substance abuse",{"count":445,"type":22},3400,[64],"The goal of this clinical trial is to explore the outcome and practice treatment for sleep-wake disturbances in a Sleep Clinic. The main questions it aims to answer are:\n\n* What is the practice (timing and duration of treatment components) of sleep-wake disturbance treatment?\n* What is the treatment effect of sleep-wake disturbance treatment.\n\nParticipants will receive treatment as usual by consultations with a trained psychiatrist or psychologist and will be asked to fill out self-reporting questionnaires and sleep diaries.",[449,450],"Insomnia Disorder","Circadian Rhythm Sleep Disorder",[449,450,452,453,454],"Sleep treatment","CBT-I","Chronotherapy","2025-06-18",{"date":457,"type":41},"2025-06-24",{"date":459,"type":41},"2025-01-01",{"date":461,"type":22},"2030-12-31",{"name":47,"class":48},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":62,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":80},"100532465","a-study-to-investigate-the-efficacy-of-pain-reduction-with-cryoneurolysis-compared-with-sham-treatment-in-adults-with-trigeminal-neuralgia-100532465","NCT06213155","A Study to Investigate the Efficacy of Pain Reduction With Cryoneurolysis Compared With Sham-treatment in Adults With Trigeminal Neuralgia","A Randomized, Parallel Arm, Sham-controlled, Double-blinded, Investigator-initiated Trial to Investigate the Safety and Efficacy of Percutaneous Peripheral Cryoneurolysis Therapy in Medically Refractory Trigeminal Neuralgia: a Pilot Study","CryoGem","Inclusion Criteria:\n\n1. Participant must be 18 years at the time of signing the informed consent\n2. A diagnosis of primary (classic and idiopathic) trigeminal neuralgia affecting the mandibular and\u002For maxillary division, verified by a neurologist\n3. Ability to subclassify the trigeminal neuralgia according to the The International Classification of Headache Disorders, 3rd edition, i.e. sufficient magnetic resonance (MR) evaluation is mandatory\n4. History of minimum mean of three trigeminal neuralgia related pain paroxysms per day last 4 weeks\n5. History of minimum average daily pain intensity NRS score (ADP) of 4 to10 last 4 weeks\n6. In baseline minimum average daily pain intensity NRS score (ADP) of 4 to 10\n7. In baseline minimum mean of three trigeminal neuralgia related pain paroxysms per day\n8. Treatment refractory as defined in this study as failure to respond, pending an adequate trial in the opinion of the investigator, contraindications or intractable side effect to one of two medications:\n\n   1. Carbamazepine\n   2. Oxcarbazepine\n9. Unaltered prophylactic TN medication regime 2 weeks prior to baseline, and be willing to keep regime unaltered during the baseline and the blinded study period.\n10. Be an appropriate candidate for the study intervention required in this study on the basis of the clinical judgment of the investigator\n11. Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\n1. Diagnosed with demyelinating inflammatory disorders such as e.g. multiple sclerosis.\n2. Other pain conditions, not intended to be treated in this study, that in the opinion of the investigator could interfere with study procedures, accurate pain reporting, and\u002For confound evaluation of study endpoints.\n3. High probability of neurological deterioration due to other medical conditions, that in the opinion of the investigator may confound outcome assessment.\n4. Patients exhibiting a high degree of comorbidity and\u002For frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator.\n5. Other coexisting current medical conditions, including, but not limited to, bleeding diathesis and thrombophilia, that presents excess procedural risk, in the opinion of the investigator.\n6. Have within 6 months of enrollment a significant untreated addiction to dependency- producing medications, alcohol, or illicit drugs.\n7. Abnormal pain behavior, inappropriate medication use and\u002For unresolved psychiatric illness, that in the opinion of the investigator are significant enough to impact perception of pain, compliance with intervention and\u002For ability to evaluate treatment outcome.\n8. Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the Gasserian ganglion.\n9. Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of a division or branch of the trigeminal nerve being targeted in this study.\n10. Facial anomaly or trauma which renders the planned procedure difficult.\n11. Subject currently has an active oral or dental abscess or a local infection at the site of injection based on present symptoms.\n12. Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past 6 months.\n13. Current participation in another treatment study\n14. Sensory deficits and\u002For pain configuration supporting, in the opinion of the neurologist, trigeminal neuropathy as more likely diagnosis.\n15. Patients with any kind of conductive implant with contraindication for nerve stimulation according to study innervation.",{"count":403,"type":22},[64],"The CryoGem Trial is a research study that tests a freezing technique called cryoneurolysis to see if it helps relieve pain in adults with trigeminal neuralgia. Trigeminal neuralgia is a condition that causes severe facial pain. In this study, we want to find out if the freezing technique is effective and safe. We will do this by comparing two groups of adults with trigeminal neuralgia. One group will receive the actual treatment, while the other group will receive a fake treatment called a sham. Neither the participants nor the assessors will know which group they are in (this is called a blinded study). For the next four weeks, participants in both groups will continue recording their headaches without knowing which treatment they are receiving. After this initial period, there will be an extension period where all participants can receive treatment as needed for up to two years. The results of this study will help us decide if the freezing technique is a viable treatment option for trigeminal neuralgia. Our main goal is to see how many people in each group have a significant reduction in pain (at least 75% less pain). We will also record other important information about the participants.\n\nWe are looking to recruit up to 24 adults with trigeminal neuralgia to take part in this study. All participants will keep a daily diary for two weeks to track their headaches before starting the treatment. Then, they will be randomly assigned to either the treatment group or the sham group.",[475],"Trigeminal Neuralgia",{"date":477,"type":41},"2025-06-19",{"date":479,"type":41},"2024-02-29",{"date":481,"type":22},"2026-12",{"name":47,"class":48},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":62,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":80},"100558727","a-study-investigating-peripheral-cryoneurolysis-in-adults-with-chronic-migraine-100558727","NCT06554886","A Study Investigating Peripheral Cryoneurolysis in Adults With Chronic Migraine","An Open Label Pilot Study Investigating the Safety and Efficacy of a Percutaneous Peripheral Cryoneurolysis Therapy in Medically Resistant Chronic Migraine","Inclusion Criteria:\n\n1. Participant must be 18 years at the time of signing the informed consent\n2. Migraine, with or without aura, fulfilling the International Classification of Headache Disorders (ICHD) III criteria 1.3. for chronic migraine at time of inclusion, verified by a neurologist\n3. History of 8 debilitating headache days per month for at least 3 consecutive months. Debilitating headache is defined as headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy at the recommended dose and taken early during the attack; failure of at least two different triptans is required.\n4. Chronic migraine at least for a period of 1 year prior to inclusion\n5. Debut of episodic migraine before the age of 50, and chronic migraine before the age of 65.\n6. The condition is pharmacologically resistant as defined in EHF guidelines as lack of efficacy, lack of tolerability and\u002For contraindications to at least 3 of the following drug classes\n\n   1. Antidepressant (Amitryptyline, Venlafaxine)\n   2. Antiepileptic (Topiramate or Valproate)\n   3. Beta-blocker (Atenol, Metropolol, Propanolol, Timolol)\n   4. Calcium channel blockers (Flunarizine or Cinnarizine)\n   5. Drugs acting on the CGRP pathway (Monoclonal antibodies and gepants)\n   6. Angiotensin-converting enzyme inhibitors (Lisinopril) or angiotensin II receptor blocker (Candesartan)\n   7. OnabotulinumtoxinA\n7. Subject has had no change in type, dosage or dose frequency of preventive headache medications \\\u003C 3 months prior to baseline\u002Fscreening, or a minimum of 5 half-lives, whichever is longer.\n8. Subjects has not been treated with steroids orally or injections \\>8 weeks (excluding steroid inhalations or topical treatments) prior to baseline and agrees to refrain from steroids orally or injections during baseline and 8 weeks post-intervention.\n9. Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency, or dose) during baseline and 8 weeks after the intervention.\n10. Be an appropriate candidate for the study intervention required in this study on the basis of the clinical judgment of the investigator\n11. Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\n1. Subject is unable to differentiate migraine from other concomitant headaches.\n2. Subject with secondary headache conditions, with the exception of medication overuse headache.\n3. Subject that, in the opinion of the investigator, has had no or minimal response to more than 6 adequate trials of prophylactic migraine treatment of the following drug classes:\n\n   1. Antidepressant (Amitryptyline, Venlafaxine)\n   2. Antiepileptic (Topiramate or Valproate)\n   3. Beta-blocker (Atenol, Metropolol, Propanolol, Timolol)\n   4. Calcium channel blockers (Flunarizine or Cinnarizine)\n   5. Drugs acting on the CGRP pathway (Monoclonal antibodies and gepants)\n   6. Angiotensin-converting enzyme inhibitors (Lisinopril) or angiotensin II receptor blocker (Candesartan)\n   7. OnabotulinumtoxinA\n4. Subject has had a change in type, dosage or dose frequency of preventive headache medications during the baseline period.\n5. Ongoing abuse of drugs (including narcotics) or alcohol.\n6. More than 4 days of opioid use per month (including codeine and tramadol), and any use of barbiturates\n7. Other pain conditions, not intended to be treated in this study, that in the opinion of the investigator could interfere with study procedures, accurate pain reporting, and\u002For confound evaluation of study endpoints.\n8. High probability of deterioration due to other medical conditions, that in the opinion of the investigator may confound outcome assessment.\n9. Other coexisting current medical conditions, including, but not limited to, bleeding diathesis and thrombophilia, that presents excess procedural risk, in the opinion of the investigator.\n10. Abnormal pain behavior, inappropriate medication use and\u002For unresolved psychiatric illness, that in the opinion of the investigator are significant enough to impact perception of pain, compliance with intervention and\u002For ability to evaluate treatment outcome.\n11. Anomaly or trauma which renders the planned procedure difficult.\n12. Subject currently has an active abscess or a local infection at the site of intervention based on present symptoms.\n13. Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving skull or site of intervention that have been active or required treatment in the past 6 months.\n14. Patients with any kind of conductive implant with contraindication for nerve stimulation.\n15. The subject is not competent to consent",{"count":491,"type":22},12,[64],"The trial is a research study that tests a freezing technique called cryoneurolysis to see if it helps relieve pain in adults with chronic migraine. Chronic migraine is a condition that causes moderate to severe headache.\n\nIn this study, the investigators want to evaluate the freezing technique in chronic migraine. The main goal is to see how much headache relief is experienced after receiving the treatment. The investigators will also record other important information about the participants.\n\nThe study is looking to recruit 12 adults with chronic migraine to take part in the study. Participants will register their headache burden in a headache diary for at least 4 weeks before receiving treatment with the freezing technique. They will continue to register headache in the headache diary during the follow-up. After this initial treatment, participants with recurring headache can receive treatment as needed for up to two years.\n\nThe results of this study will help us decide if the freezing technique may be viable treatment option for chronic migraine and enable us plan for further studies on this treatment.",[428],"2025-06-17",{"date":457,"type":41},{"date":498,"type":41},"2024-08-29",{"date":500,"type":22},"2027-02",{"name":47,"class":48},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":57,"minAge":510,"maxAge":511,"enrollmentInfo":512,"targetDuration":4,"studyType":62,"phases":514,"briefSummary":516,"conditions":517,"keywords":520,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":532},"100354042","phase-4-innovative-steroid-treatment-to-reduce-asthma-development-in-children-after-first-time-rhinovirus-induced-wheezing-100354042","NCT03889743","Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing","Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing - the INSTAR Study","INSTAR","Inclusion Criteria:\n\n* admitted to pediatric acute wards in the participating hospitals in Norway, Finland, Sweden.\n* referred for first severe wheezing episode, defined as first-time acute breathing difficulty with wheezing ever, appearing less than 7 days from onset of symptoms\n* one or more of the following:(a) fever, (b) hypoxia (SAT O2 \\\u003C= 92%), (c) retractions (inter-, subcostal), (d) prolonged expiration (on auscultation), (e) expiratory rhonchi (on auscultation)\n* evidence of rhinovirus infection by PCR-test in nasopharyngeal secretions\n* signed informed consent and expected cooperation of the patients for the treatment and follow-up must be obtained and documented according to ICH GCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* previous episodes with wheezing, defined as a history of acute breathing difficulty with wheezing in need of treatment at a general practitioner or at hospital, or parental information about similar breathing difficulties\n* gestational age \\\u003C37 weeks\n* chronic illness other than atopy (eczema),\n* previous systemic or inhaled corticosteroid treatment,\n* participation to another trial,\n* varicella infection or contact during the last 2-3 weeks,\n* need for intensive care unit treatment during the present infection, except for respiratory support with non-invasive methods (high flow nasal cannula ventilation, CPAP or BiPAP),\n* any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures).\n* COVID-19 related disease.","3 Months","23 Months",{"count":513,"type":22},280,[515],"PHASE4","The overall objective of the study is to determine the efficacy of corticosteroids in preventing recurrent wheezing and asthma in high-risk, first-time severe wheezing children with rhinovirus infection, stratified by rhinovirus genome load.\n\nThe secondary objectives are to determine duration and severity of each acute episode with acute expiratory breathing difficulty, the number of episodes with acute expiratory breathing difficulty, degree of pulmonary hyperreactivity and quality of life within 24 months after study entry.",[518,519],"Asthma","Inflammation",[521,522,523],"Respiratory Sounds","Steroids","Rhinovirus","2025-06-10",{"date":526,"type":41},"2025-06-13",{"date":528,"type":41},"2019-05-08",{"date":530,"type":22},"2028-05",{"name":47,"class":48},8,{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":62,"phases":543,"briefSummary":544,"conditions":545,"keywords":549,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":80},"100567743","initial-double-sequential-external-defibrillation-in-out-of-hospital-cardiac-arrest-100567743","NCT06672159","Initial Double Sequential External Defibrillation in Out of Hospital Cardiac Arrest","A Randomized Controlled Trial on Early Double External Sequential Defibrillation in Out of Hospital Cardiac Arrest","DUALDEFIB","Inclusion Criteria:\n\n* Patients with out of hospital cardiac arrest presenting with a shockable rhythm\n\nExclusion Criteria:\n\n* Age below 18 years\n* Obvious or suspected pregnancy\n* Incarcerated patients\n* Preexisting do-not-resuscitate order",{"count":542,"type":22},356,[64],"Double Sequential External Defibrillation (DSED) represents an alternative treatment of refractory ventricular fibrillation (rVF) in out-of-hospital cardiac arrest (OHCA). The procedure consists of two defibrillators that administer shocks at the same time.\n\nCurrently, the procedure is not initiated before at least three failed attempts with one defibrillator. This can delay the potential benefits of establishing DSED earlier in the treatment. Studies have shown that early defibrillation is crucial for survival in OHCA patients, and in 2022, a clinical trial showed that survival in patients treated with DSED was higher compared to standard treatment.\n\nThe effect of initiating OHCA treatment is unknown. The DUALDEFIB trial seeks to investigate if treating OHCA patients with DSED as an initial treatment will increase survival and provide improved neurological outcome.",[546,547,548],"Cardiac Arrest","Out-Of-Hospital Cardiac Arrest","Ventricular Fibrillation",[550,551],"Double defibrillation","Cardiopulmonary resuscitation","2025-06-04",{"date":554,"type":41},"2025-06-05",{"date":556,"type":41},"2025-04-28",{"date":558,"type":22},"2028-10",{"name":47,"class":48},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":124,"enrollmentInfo":567,"targetDuration":4,"studyType":62,"phases":569,"briefSummary":570,"conditions":571,"keywords":575,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":588,"locationsCount":80},"100532429","evaluation-of-a-digital-pre-therapy-patient-education-program-starthjelp-in-outpatient-mental-health-care-100532429","NCT06212687","Evaluation of a Digital Pre-therapy Patient Education Program (StartHjelp) in Outpatient Mental Health Care","StartHjelp","Inclusion Criteria:\n\n* Put on the waiting list for mental health outpatient treatment in the active study period.\n* Willing to participate in the study\n* Over 18 years\n* Understand written and spoken Norwegian\n\nExclusion Criteria:\n\n* In need of acute help",{"count":568,"type":22},170,[64],"Community mental health centers (CMHCs) face significant challenges in meeting the needs of individuals with mental health issues. For example, due to high demand, there are long waiting lists and low engagement rates. Innovative interventions are urgently needed to address these challenges to improve patient engagement, coping skills, and overall health outcomes. Educational and self-management interventions have shown promise in enhancing patient activation and treatment satisfaction in other contexts. They may therefore be potential solutions to reduce the identified challenges in the mental health service. To bridge these knowledge and practice gaps, this study aims to evaluate a digital pre-therapy patient education program tailored specifically for adults with mental disorders. This intervention aims to enhance treatment satisfaction, patient activation, knowledge, patient engagement, and overall mental health outcomes.",[572,573,574],"Mental Health Issue","Mental Disorder","Patient Education",[576,577,578,579,580,581,582],"Patient education","Patient Satisfaction","Self Efficacy","Pre-therapy","DIgital health","Mental health","Therapy preparation",{"date":584,"type":41},"2025-06-08",{"date":586,"type":41},"2024-12-15",{"date":348,"type":22},{"name":47,"class":48},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":89,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":62,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":80},"100524455","screening-for-preeclampsia-in-norway-with-aspirin-discontinuation-at-24-28-weeks-100524455","NCT06108947","Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks","Implementing Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks - a Randomized Controlled Trial","PEScreenNor","Inclusion Criteria\n\n* 18 years or older\n* singleton live fetus with gestational age between 24 and 28 weeks\n* woman with high risk of preterm preeclampsia (\\>1\u002F100) in the first trimester screening\n* aspirin treatment with a dose 150 mg per day initiated at 16+6 weeks of gestation or less until randomization with adherence of at least 50%\n* low SFlt-1\u002FPlGF ratio (Kryptor technology with cut-off 66) measured at 24-28 weeks\n\nExclusion Criteria\n\n* not speaking Norwegian or English language\n* fetal anomalies diagnosed with ultrasound\n* informed consent for participation in the trial",{"count":308,"type":22},[64],"Study population Around 3500 pregnant women attending a routine ultrasound scan at 11-14 weeks at St. Olavs hospital, Trondheim, Norway.\n\nStudy period Dec 2023 - Jul 2025\n\nScreening Patient history, blood pressure, uterine artery mean PI and PlGF will be plotted in the FMF algorithm for screening for preeclampsia in the first trimester. Standardized blood pressure will be measured by trained personnel. Ultrasound scans will be performed by FMF certified doctors and midwives working at the Center for Fetal Medicine in Trondheim. Placenta growth factor (PLGF) will be analyzed with Kryptor technology at Center for Laboratory Medicine, St. Olavs hospital.\n\nProphylaxis Women with high risk for preterm preeclampsia (risk \\> 1:100) will be offered aspirin prophylaxis 150 mg x 1 from 11-14 weeks to 36 weeks. Women will be offered to participate in a randomized controlled trial (RCT).\n\nStudy design and participants in the RCT A single center, open label, randomized, noninferiority trial conducted at St. Olavs hospital, Trondheim Norway from Dec 2023 to Jul 2025. The investigators will include around 300 women 18 years or older with a singleton live fetus, gestational age between 24 and 28 weeks, high risk of preterm preeclampsia (\\>1\u002F100) in the first trimester screening, aspirin treatment with a dose 150 mg per day initiated at 16+6 weeks of gestation or less until randomization with a adherence of at least 50% and low SFlt-1\u002FPlGF ratio (Kryptor technology with cut-off 66).\n\nRandomization and masking Between 24 and 28 weeks of gestation, participants will be randomly designed, with a computer-based system in a 1:1 ratio, to continue aspirin (control group) or discontinue aspirin (intervention group). This is an open-label study without masking of patients or providers.\n\nFollow-up Both groups will have visits every 4 weeks between randomization and 36 weeks, and standard antenatal care after 37 weeks until delivery. Treatment adherence will be assessed by patient self-report and tablet count, and fetal growth and Doppler will be assessed at the scheduled visits between randomization and 36 weeks (at 24, 28, 32 and 36 weeks), and according to clinical judgement by obstetricians at the outpatient clinic of the hospital. Women will have a telephone\u002Fvideo link follow-up 1-2 months after birth",[601],"Pre-Eclampsia",{"date":554,"type":41},{"date":604,"type":41},"2024-01-01",{"date":606,"type":22},"2027-06",{"name":47,"class":48},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":4,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":615,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":617,"conditions":618,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":622,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":416},"100505957","effects-and-cost-effectiveness-of-e-meistring---a-guided-internet-delivered-psychological-treatment-100505957","NCT05868135","Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment","Guided Internet-delivered Treatment for Moderate Depression, Social Anxiety Disorder and Panic Disorder - An Open Naturalistic Multicentre Cost-effectiveness Trial","Inclusion Criteria:\n\nHaving moderate depression, panic disorder and social anxiety disorder as a primary disorder. Access to computer and internet.\n\nExclusion Criteria:\n\nHaving severe depression, suicidal impulses and thoughts, bipolar disorders, psychosis, substance abuse, unstable medication last month, severe reading or writing disabilities.",{"count":616,"type":22},800,"The goal of this observational multicentre study is to address the effectiveness and cost-effectiveness of providing a therapist guided internet based cognitive behavioural therapy (ICBT) for common mental disorders in a routine healthcare setting.\n\nMain research questions is 1) What is the effectiveness of guided internet based treatment for moderate depression, panic disorder and social anxiety disorder across clinics in routine care? 2) What is the cost-effectiveness of guided internet based treatment for moderate depression, panic disorder and social anxiety disorder across clinics? 3) Who benefits from guided internet-delivered treatment? 4) What are the predictors of drop-out from guided internet based treatment? 5) To what extent does user experiences of guided internet based treatment influence adherence and effectiveness? Participants will receive up to nine guided ICBT sessions (modules) and answer questionnaires covering symptoms severity, health related quality of life, work and social ability, user satisfaction and medication. All questionnaires are part of the standard patient follow up routines in the four treatment locations participating in the study. Analytical approach is to compare locations\u002Fclinics and subgroups of patients.",[619,620,621],"Depression Moderate","Anxiety, Social","Panic Disorder",{"date":554,"type":41},{"date":624,"type":41},"2021-09-09",{"date":626,"type":22},"2027-12-31",{"name":47,"class":48},{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":57,"minAge":635,"maxAge":636,"enrollmentInfo":637,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":639,"conditions":640,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":643,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":80},"100505504","gastrocnemius-tightness-and-foot-pain-in-children-100505504","NCT05862246","Gastrocnemius Tightness and Foot Pain in Children","Is There an Association Between Gastrocnemius Tightness and Foot- and Legpain in Children?","Inclusion Criteria:\n\n* Otherwise healthy children referred to pediatric orthopaedic outpatient clinic with foot and\u002For leg pain with a normal leg function\n\nExclusion Criteria:\n\n* Patients with foot conditions, general medical conditions affecting the foot or clinical findings indicating a need for further investigation for a diagnosis. Such as:\n\nFoot deformities (cavo-varus foot, clubfoot) Tarsal coalitions Neuro-orthopedic conditions (CP, MMC) Fracture sequelae Infections and tumour","4 Years","16 Years",{"count":638,"type":22},200,"Foot and leg pain among otherwise healthy children is a common reason for referral to our pediatric orthopaedics outpatient clinic. The pain is often intermittent and transient, but for some the pain is more dominating and has an impact on the child and families. Children grown and have normal anatomical variations such as in-toeing, out-toeing, hypermobility, flatfeet, knock knees etc. Assessing such normal variants is a major part of pediatric orthopaedic practice, and a common finding is a positive Silvferskiöld test, indicating gastrocnemius tightness. This is when dorsiflexion of the ankle is limited with extended knee, compared to flexed knee. We do not know if this is a more frequent finding among children with foot and leg pain. There is however evidence that adults with painful foot conditions often have gastrocnemius tightness.\n\nThis project will investigate for gastrocnemius tightness in otherwise healthy children referred to our pediatric orthopaedic outpatient clinic with foot and leg pain, and compare results with a similar control group of children without pain. The aim is to investigate if there is an association, and how pain and tightness develops over time. The knowledge from this project will enable us to develop new treatment strategies to this patient group, where current evidence based recommendations are few.",[641,642],"Child Development","Gastrocnemius Equinus",{"date":554,"type":41},{"date":645,"type":41},"2023-05-09",{"date":647,"type":22},"2028-06",{"name":47,"class":48},""]